The method for assaying potency of anti-HBs immunoglobulin (HBIG) developed in our Department was applied to the standardization of the Japanese national reference HBIG preparation which is specified in the Minimum Requirements for Biological Products . The method was studied for utility in routine anti-HBs determination.
INTRODUCTION
Although there is an agreement on the effectiveness of anti-HBs immunoglobulin (HBIG) in such post-exposure prevention of hepatitis B as one after accidental needle pricks, further study will be needed to see if its efficacy in other occasions of hepatitis B infection can be established as well. There may be such a wide range in the in .fectivity of the source of infection, on the one hand, and a level of exact quantitation does not seem to have been attained by everyone in expressing anti-HBs antibody content of HBIG , on the other.
In a previous report , we described a method for potency determination of HBIG by radioimmunoassay (RIA) by applying the parallel line assay method (Finney, 1964) . As the International Reference Preparation of HBIG (hereafter referred to as IRHBIG) was not available when we started our work, comparison was then made with the Reference Preparation Lot 2 supplied by the Bureau of Biologics, U.S. Food and Drug Administration (hereafter referred to as Bob-2) from which IRHBIG is said to have been prepared (WHO/BS/77.1164).
Although it is theoretically possible to calculate the potency of BoB-2 from the units assigned to IRHBIG, Lot 26-1-77 (50 IU/ampoule reconstituted to 0.5ml) by multiplying by 3.667, which is the protein concentration ratio of the former to the latter (16.5/4.5), there has been no official information concerning the potency in international units of the former. Therefore, we tried direct comparison between IRHBIG and our proposed National Reference HBIG (hereafter referred to as NRHBIG) to which international units had to be assigned. As the outcome of our work in this direction, the Monograph for HBIG along with the designation of NRHBIG was added to the Minimum Requirements for Biological Products (MRBP) (Ministry of Health and Welfare, 1979) in 1980. In this report, the results of our experiments in the process of standardization of NRHBIG will be presented. It is also attempted to demonstrate the utility of NRHBIG in potency testing of commercial HBIG preparations and to assure its stability. of the relative potency 
Potencies of Several HBIG Preparations
The potencies of 17 preparations submitted by four manufacturers were estimated in terms of IU in several separated experiments . NRHBIG was used as the reference in every experiment and the potencies of preparations were calculated always from the relative potencies to NRHBIG to which 108 IU/ml was assigned as stated above (Table IV) . The variance analyses demonstrated no significant deviations either from linearity or parallelism of the dose -response lines of all the preparations, including NRHBIG . Table IV shows also anti-HBs antibody titers determined by passive hemagglutination (PHA) as stated by each of the manufacturers. There may be differences among the manufacturers in regards to the correlation of their PHA titers to our RIA values. Though the overall correlation coefficient was 0.713, when a pair of isolated values (see Fig. 2 ) was excluded, the coefficient became 0.345. It must be noted that, with preparations of a fixed PHA titer of, e.g. 16,000, the RIA values distributed from about 100 IU /ml to nearly 400 IU/ml, and with another group with a PHA titer of 32,000, from about 450 to about 710IU/ml. The PHA titers obtained by individual manufacturers did not well correlate to the IU values obtained by us by the parallel line assay method using RIA. Though there may be several possible interpretations, the data so far available are not large enough to draw any conclusion. We are by no means insisting upon that only RIA can be used in the potency test of HBIG. To apply a parallel line assay method to PHA, some new device would be necessary. The device used by Uemura et al. (1980) is an example, in which the size of agglutinated red cell mass formed in the bottom of the tube or the well was taken as a graded response (Takahashi et al., 1975) , though the precision of the estimate was somewhat lower than those of ours and of Barker et al. (1978) . Such techniques as enzyme immunoassay and single radial immunodif£usion may provide additional methods for the potency test of HBIG to which parallel line assay may also be applied.
In the past, a series of experiments was carried out by a Project Team on the stability of equine diphtheria-, tetanus-, and gas gangrene antitoxin preparations in an experimental design based on the accelerated degradation test (Jerne and Perry, 1956; Greif and Rightsel, 1965) . The half life of the potency at 5 C was calculated according to the hypothesis that Arrhenius' theory can be applied to the degradation process of test materials. Then, the half life of the antitoxin preparations tested was estimated to be longer than several thousand years since they had shown 10-20% loss in potency upon heating at 60 C for 10 min (Murata et al., personal communication) . In comparison with these data of antitoxins, our NRHBIG appears to be satisfactorily stable, since its potency was unaffected by heating at 60 C for 6 hr.
